ClinicalTrials.gg

Program

apecotrep

Also written as “BI 764198”, “BI 764198 - Formula A” and “BI 764198 - Formula B”.

In Boehringer Ingelheim's pipeline, TRPC6 inhibitor. Its studies are mostly in Renal Insufficiency, Chronic · Glomerulosclerosis, Focal Segmental · COVID-19, led by Boehringer Ingelheim.

Furthest: phase 3, since Oct 22, 202513 company-led studies, 2 open or runningNext primary completion: Jan 20, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Boehringer Ingelheim132 open or runningphase 3since Oct 22, 2025Feb 25, 2019Jan 20, 2028phase 2 · NCT07355296
  • Named in Boehringer Ingelheim’s own pipeline as Apecotrep (BI 764198), phase 3, as of Aug 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 25, 2019First study: phase 1 study in HealthyFirst studyNCT03854552 · 72 enrolled · Germany
  2. Sep 24, 2019Phase 1 study in HealthyNCT04102462 · 52 enrolled · Germany
  3. Nov 22, 2019Phase 1 study in Renal Insufficiency, ChronicNCT04176536 · 28 enrolled · Germany
  4. Oct 26, 2020Phase 2 study in COVID-19NCT04604184 · 133 enrolled · United States, Brazil, Chile and more
  5. Dec 1, 20202 phase 1 studies in HealthyNCT04656288, NCT04665700
  6. Jan 27, 2022Phase 2 study in Renal Insufficiency, ChronicNCT05213624 · 67 enrolled · United States, Australia, Belgium and more
  7. Apr 25, 2023Phase 1 study in HealthyNCT05863130 · 24 enrolled · Netherlands
  8. Apr 25, 2025Phase 1 study in HealthyNCT06955754 · 16 enrolled · Germany
  9. Oct 22, 2025Phase 3 study in Glomerulosclerosis, Focal SegmentalNCT07220083 · 286 planned · United States, Argentina, Australia and more
  10. Dec 17, 2025Phase 1 study in HealthyNCT07308652 · 14 enrolled · Germany
  11. Jan 20, 2026Phase 1 study in HealthyNCT07368569 · 14 enrolled · Germany
  12. Jan 20, 2026Phase 2 study in Proteinuric Kidney DiseasesNCT07355296 · 132 planned · United States, Argentina, Australia and more

Ahead

  1. Jan 20, 2028Primary completion: phase 2 study in Proteinuric Kidney DiseasesNCT07355296
  2. Dec 27, 2028Primary completion: phase 3 study in Glomerulosclerosis, Focal SegmentalNCT07220083

TargetBeta

“TRPC6 inhibitor”the company's pipeline, read by Claude · source

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07368569Healthy · Germany1CompletedMar 14, 202614
NCT07355296Proteinuric Kidney Diseases · United States, Argentina, Australia and more2RecruitingJan 20, 2028132
NCT07308652Healthy · Germany1CompletedMar 24, 202614
NCT07220083Glomerulosclerosis, Focal Segmental · United States, Argentina, Australia and more3RecruitingDec 27, 2028286
NCT06955754Healthy · Germany1CompletedJun 26, 202516
NCT05863130Healthy · Netherlands1CompletedNov 9, 202324
NCT05213624Renal Insufficiency, Chronic · United States, Australia, Belgium and more2CompletedJan 3, 202567
NCT04665700Healthy · Japan1CompletedOct 16, 202144
NCT04656288Healthy · Belgium1CompletedMar 15, 202128
NCT04604184COVID-19 · United States, Brazil, Chile and more2TerminatedMar 24, 2021133
NCT04176536Renal Insufficiency, Chronic · Germany1CompletedNov 17, 202028
NCT04102462Healthy · Germany1CompletedOct 8, 202052
NCT03854552Healthy · Germany1CompletedAug 7, 201972

How it is read

Names in the registry

  • “BI 764198”, 10 entries
  • “BI 764198 - Formula A”, 1 entry
  • “BI 764198 - Formula B”, 1 entry
  • “BI 764198 - Formula C”, 1 entry
  • “BI 764198 - Formula D”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.